Sarepta Therapeutics Securities Class Action Lawsuit

The Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. (NASDAQ: SRPT) between June 22, 2023, and June 24, 2025, of the important August 25, 2025, lead plaintiff deadline. The lawsuit alleges that Sarepta made false and misleading statements about its prescription gene therapy, ELEVIDYS, which posed significant safety risks to patients.

Key Takeaways:

• The lawsuit claims that Sarepta made false and misleading statements about ELEVIDYS, including its safety risks, trial regimes, and regulatory scrutiny.
• The defendants allegedly lacked a reasonable basis for their positive statements about ELEVIDYS, causing investors to suffer damages.
• The lawsuit seeks compensation for investors who purchased Sarepta securities during the Class Period without payment of any out-of-pocket fees or costs through a contingency fee arrangement.
• The Rosen Law Firm represents investors throughout the globe and has a track record of success in securities class actions, including a $438 million recovery for investors in 2019.
• The lawsuit has been filed, and a lead plaintiff is being sought to direct the litigation.
• Investors who have not selected counsel may select qualified counsel with a track record of success in leadership roles.

Statistics:

• The Class Period spans from June 22, 2023, to June 24, 2025.
• The lawsuit alleges that investors suffered damages due to Sarepta's false and misleading statements about ELEVIDYS.
• In 2019, the Rosen Law Firm secured over $438 million for investors in a securities class action lawsuit.
• The Rosen Law Firm has recovered hundreds of millions of dollars for investors in securities class actions.

Sources:

• Newsfile Corp. - August 23, 2025
• Rosenlegalfirm.com - details of the case and further information about the lead plaintiff deadline
• LinkedIn - The Rosen Law Firm profile
• Twitter - @rosen_firm
• Facebook - @rosenlawfirm